Literature DB >> 10730544

Important drug interactions in dermatology.

T C Roos1, H F Merk.   

Abstract

Drug interactions can occur at any step from absorption to elimination of a drug, and can induce adverse as well as beneficial effects. Since systemic drugs are increasingly available and important in the treatment of dermatological diseases, a variety of possible interactions between concomitantly administered drugs have to be considered by dermatologists. The xenobiotic-metabolising enzyme system cytochrome P450 (CYP) is involved in the metabolism of many drugs, regulating their plasma concentrations and activities. Furthermore, the adverse effects of many drugs depend on the basal activity and inducibility of particular CYP isoenzymes in an individual patient. Since drug therapy in dermatological practice is of increasing complexity, and an increasing number of potent systemic drugs have become commonly used therapeutic agents, this review focuses on the following topics with the aim of optimising dermatological drug therapy. In the first section, all the different types of drug interactions that can occur through pharmacokinetic and pharmacodynamic mechanisms are introduced briefly, and then discussed systematically with special reference to drugs important for dermatologists. Then, the network of drug interactions that may occur from absorption to elimination is presented. The most important drug interactions mediated by CYP isoenzymes are listed. Finally, the importance of pharmacogenetics for the development of new drugs and its potential impact on the optimisation of individual therapy regimens is discussed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10730544     DOI: 10.2165/00003495-200059020-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  29 in total

1.  In vitro inhibition of dihydropyridine oxidation and aflatoxin B1 activation in human liver microsomes by naringenin and other flavonoids.

Authors:  F P Guengerich; D H Kim
Journal:  Carcinogenesis       Date:  1990-12       Impact factor: 4.944

2.  Itraconazole and anti-tuberculosis drugs.

Authors:  M Blomley; E L Teare; A de Belder; Y Thway; M Weston
Journal:  Lancet       Date:  1990-11-17       Impact factor: 79.321

Review 3.  Retinoid metabolism in the skin.

Authors:  T C Roos; F K Jugert; H F Merk; D R Bickers
Journal:  Pharmacol Rev       Date:  1998-06       Impact factor: 25.468

Review 4.  P450 inhibitors of use in medical treatment: focus on mechanisms of action.

Authors:  H Vanden Bossche; L Koymans; H Moereels
Journal:  Pharmacol Ther       Date:  1995       Impact factor: 12.310

5.  Coadministration of rifampin and itraconazole leads to undetectable levels of serum itraconazole.

Authors:  J Drayton; G Dickinson; M G Rinaldi
Journal:  Clin Infect Dis       Date:  1994-02       Impact factor: 9.079

Review 6.  Antifungal therapy: potential interactions with other classes of drugs.

Authors:  D R Bickers
Journal:  J Am Acad Dermatol       Date:  1994-09       Impact factor: 11.527

Review 7.  Oral azole drugs as systemic antifungal therapy.

Authors:  J A Como; W E Dismukes
Journal:  N Engl J Med       Date:  1994-01-27       Impact factor: 91.245

8.  Mechanism of the cardiotoxic actions of terfenadine.

Authors:  R L Woosley; Y Chen; J P Freiman; R A Gillis
Journal:  JAMA       Date:  1993 Mar 24-31       Impact factor: 56.272

Review 9.  Pharmacokinetic drug interactions of macrolides.

Authors:  P Periti; T Mazzei; E Mini; A Novelli
Journal:  Clin Pharmacokinet       Date:  1992-08       Impact factor: 6.447

Review 10.  Antiepileptic drugs. A review of clinically significant drug interactions.

Authors:  P N Patsalos; J S Duncan
Journal:  Drug Saf       Date:  1993-09       Impact factor: 5.606

View more
  3 in total

1.  Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism-dependent haptenation and T-cell proliferation in vivo.

Authors:  D J Naisbitt; S F Gordon; M Pirmohamed; C Burkhart; A E Cribb; W J Pichler; B K Park
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

Review 2.  Recent advances in treatment strategies for atopic dermatitis.

Authors:  Thomas Christian Roos; Stefan Geuer; Sabine Roos; Harald Brost
Journal:  Drugs       Date:  2004       Impact factor: 9.546

3.  Drug interactions in dermatology: what the dermatologist should know.

Authors:  Arijit Coondoo; Chandan Chattopadhyay
Journal:  Indian J Dermatol       Date:  2013-07       Impact factor: 1.494

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.